Welcome to our dedicated page for LeonaBio news (Ticker: LONA), a resource for investors and traders seeking the latest updates and insights on LeonaBio stock.
LeonaBio, Inc. reports clinical-stage biopharmaceutical developments focused on novel therapeutics for diseases with high unmet medical needs. The company’s news centers on lasofoxifene, a selective estrogen receptor modulator being developed for treatment-resistant ER-positive, HER2-negative, ESR1-mutated metastatic breast cancer, along with broader pipeline work that includes small-molecule neurology candidates such as ATH-1105 and ATH-1020.
Recurring updates cover clinical and nonclinical data, oncology research presentations, key opinion leader events, financial results, licensing activity, private financing, board and executive changes, and the completed name and ticker transition from Athira Pharma to LeonaBio and LONA.
LeonaBio (NASDAQ: LONA) appointed Mark F. Kubik as Chief Business Officer effective Feb 3, 2026. Kubik brings more than 25 years of biopharma business development and corporate strategy experience and will lead licensing, partnerships, and corporate development.
He served as a strategic consultant and helped execute the December 2025 transformational transaction that gave LeonaBio rights to the Phase 3 lasofoxifene program for metastatic breast cancer. Management says Kubik will support advancing lasofoxifene in Phase 3 and expanding a diversified oncology and neurodegeneration pipeline.
Athira Pharma (NASDAQ: ATHA) changed its name to LeonaBio and will trade under new ticker LONA beginning January 12, 2026.
The name change follows a transformative exclusive license for lasofoxifene (Phase 3 ELAINE-3, >50% enrolled; topline data expected mid-2027) and an upfront private placement of $90 million plus warrants that could provide up to $146 million if fully exercised to fund development through key milestones into 2028.